Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934701 | 0.81 | PPARA (0.59) | PPARDPPARGPPARA | |
| SCHEMBL2032304 | 0.81 | PDE4A (0.39) | ALDH1A1NPC1RAB9AHAO1PPARD | |
| SCHEMBL3937950 | 0.80 | HAO1 (0.42) | POLBNPC1RAB9AHAO1THRB | |
| SCHEMBL13534917 | 0.77 | ALDH1A1 (0.57) | ALDH1A1POLBPPARDKDM4ETHRB | |
| SCHEMBL3974921 | 0.75 | PPARG (0.67) | ALDH1A1POLBNPC1RAB9APPARD | |
| SCHEMBL3974924 | 0.75 | PPARG (0.67) | ALDH1A1POLBNPC1RAB9APPARD | |
| SCHEMBL2027258 | 0.74 | PPARA (0.35) | ALDH1A1POLBNPC1RAB9AHAO1 | |
| SCHEMBL21017557 | 0.74 | ALDH1A1 (0.36) | ALDH1A1POLBPPARDPPARGPPARA | |
| SCHEMBL1934452 | 0.74 | PPARA (0.44) | ALDH1A1NPC1RAB9AHAO1PPARD | |
| SCHEMBL3865193 | 0.74 | NPC1 (0.64) | ALDH1A1FFAR1FFAR4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046715-B1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-07-17 | — | — | US | disclosed |
| EP-2641596-B1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-05-02 | — | — | EP | disclosed |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-12-28 | — | — | US | disclosed |
| US-9782373-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-10-10 | — | — | US | disclosed |
| EP-2641596-A1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | Genfit (FR) | 2013-09-25 | — | — | EP | disclosed |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2012-10-04 | — | — | US | disclosed |
| EP-2504005-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | Genfit (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-8258182-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258182-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-09-04 | — | — | US | disclosed |
| WO-2011080276-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DPP-4 INHIBITOR AND A 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE | GENFIT (FR) | 2011-07-07 | — | — | WO | disclosed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | disclosed |
| WO-2011064350-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2011-06-03 | — | — | WO | disclosed |
| WO-2007147879-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP4, CYP3A43 | S1PR1 1152/4885ALDH1A1 26/4885POLB 2370/4885 |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT1, GOT2 | S1PR1 2773/4885ALDH1A1 79/4885POLB 2653/4885 |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | S1PR1 1686/4885ALDH1A1 34/4885POLB 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.